GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » Net-Net Working Capital

Taiko Pharmaceutical Co (TSE:4574) Net-Net Working Capital : 円36.91 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Taiko Pharmaceutical Co's Net-Net Working Capital for the quarter that ended in Mar. 2024 was 円36.91.

The industry rank for Taiko Pharmaceutical Co's Net-Net Working Capital or its related term are showing as below:

TSE:4574's Price-to-Net-Net-Working-Capital is ranked worse than
60.83% of 411 companies
in the Drug Manufacturers industry
Industry Median: 7.02 vs TSE:4574: 10.16

Taiko Pharmaceutical Co Net-Net Working Capital Historical Data

The historical data trend for Taiko Pharmaceutical Co's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co Net-Net Working Capital Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 135.69 153.72 189.45 23.23 -26.93

Taiko Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.93 10.60 24.73 23.57 36.91

Competitive Comparison of Taiko Pharmaceutical Co's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiko Pharmaceutical Co's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Taiko Pharmaceutical Co's Price-to-Net-Net-Working-Capital falls into.



Taiko Pharmaceutical Co Net-Net Working Capital Calculation

Taiko Pharmaceutical Co's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net-Net Working Capital(A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3505+0.75 * 1798+0.5 * 1952-7003
-0-0)/43.5758
=-26.93

Taiko Pharmaceutical Co's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(5238+0.75 * 1935+0.5 * 1472-5574
-0-0)/50.1497
=36.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Taiko Pharmaceutical Co  (TSE:4574) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Taiko Pharmaceutical Co Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiko Pharmaceutical Co (TSE:4574) Business Description

Traded in Other Exchanges
N/A
Address
No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co (TSE:4574) Headlines

No Headlines